Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

CNBX Pharmaceuticals (CNBX) Debt Ratio (2016 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed Debt Ratio for 7 consecutive years, with 41.27 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Debt Ratio rose 1432.78% year-over-year to 41.27, compared with a TTM value of 41.27 through Aug 2024, up 1432.78%, and an annual FY2024 reading of 41.27, up 1432.78% over the prior year.
  • Debt Ratio was 41.27 for Q3 2024 at CNBX Pharmaceuticals, up from 2.69 in the prior quarter.
  • Across five years, Debt Ratio topped out at 41.27 in Q3 2024 and bottomed at 0.15 in Q1 2021.
  • Average Debt Ratio over 4 years is 4.87, with a median of 1.84 recorded in 2023.
  • The sharpest move saw Debt Ratio grew 21.12% in 2023, then skyrocketed 1432.78% in 2024.
  • Year by year, Debt Ratio stood at 0.5 in 2021, then skyrocketed by 473.94% to 2.89 in 2022, then dropped by 6.93% to 2.69 in 2023, then surged by 1432.78% to 41.27 in 2024.
  • Business Quant data shows Debt Ratio for CNBX at 41.27 in Q3 2024, 2.69 in Q3 2023, and 2.01 in Q2 2023.